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Background: Pretreatment evaluation of HCV-infected patients is a complex interplay between multiple clinical
and viral parameters, leading to a tailored approach that may bring real-life sustained virological response (SVR)
rates close to 98%–99%.
Objectives: As proof-of-concept, we evaluated the efficacy of all-oral direct-acting antiviral (DAA) regimens in
patients whose personalization included pre-therapy evaluation of natural resistance-associated substitutions
(RASs), in addition to international guideline recommendations.
Methods: One hundred and thirty-one patients who started a first-line all-oral DAA regimen between April 2015
and December 2016 were tested for baseline NS3 and NS5A RASs by Sanger sequencing. SVR12 was defined as
HCV-RNA undetectability 12 weeks after treatment discontinuation.
Results: Compatibly with a real-life context, 74.0% (97 of 131) of patients presented 2 pretreatment risk fac-
tors for failure to achieve SVR12 (infection by GT-1a/GT-3a; cirrhosis; previous treatment experience; HCV-RNA
800000 IU/mL) and 33.6% had 3 risk factors. Natural RASs were frequently detected (32.1% prevalence),
with substantial prevalence of NS5A RASs (15.3%), mostly represented by Y93H in GT-1b (3 of 36, 8.3%) and
GT-3a (3 of 25, 12.0%) and F28C in GT-2c (2 of 11, 18.2%). Overall, personalized treatment led to 100% SVR12,
even in those patients for whom treatment strategy was either strengthened (by ribavirin inclusion and/or dur-
ation increase) or simplified (by ribavirin exclusion and/or duration reduction), thanks to baseline RAS evaluation.
Conclusions: Even with newer DAA regimens, an integrated interpretation of clinical and virological pretreat-
ment parameters, including natural RASs, may play a relevant role in bringing SVR rates close to the highest
achievable. Treatment tailoring can be foreseen in ‘hard-to-treat’ patients, but also in ‘easy’ patients with favour-
able indicators, whereby a simplification/shortening of recommended regimens can be indicated.
Introduction
DAA-based treatment represents a major breakthrough in the
treatment of HCV infection, bringing sustained virological response
(SVR) rates beyond the threshold of 90%. Despite that, 100000
virological failures have been predicted by 2020 in the USA,1 the
most of which will be NS5A failures with limited retreatment op-
tions due to development of resistance-associated substitutions
(RASs). Therefore, management of modern direct-acting antivirals
(DAAs) can still be improved.
Clinical and viral parameters were used to tailor anti-HCV treat-
ment since the IFN era, and then reconsidered as last-generation
DAAs became available. Some parameters, such as IL28B genotype
and on-treatment viral response, lost importance, while others,
such as HCV genotype, baseline HCV-RNA, liver disease severity and
previous treatment experience, kept significance and are still used
to modulate treatment schedules.2,3 Lastly, new viral characteris-
tics emerged as clinically significant. Among these, baseline geno-
typic resistance testing (GRT) for natural RASs before the first DAA
course can help physicians to guide treatment decisions,2,3 as
some NS3 and (more importantly) NS5A RASs were shown to re-
duce significantly the SVR rates to NS3 PIs and NS5A inhibitors.4–8
Natural RAS relevance was shown to depend greatly upon the
DAA used, HCV genotype and subtype, previous treatment experi-
ence and baseline HCV-RNA, making pretreatment evaluation of
HCV-infected patients a complex interplay between multiple clin-
ical and viral parameters. This holds true in complex patients
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(comorbidities, advanced liver disease, first-generation DAA fail-
ures etc.), but also in easy-to-treat patients, in light of the ten-
dency to decrease the duration of treatment (who should undergo
short therapy, and who should not). Under these conditions, a tail-
ored approach in some (not infrequent, though) real-life situations
may help in bringing the cure rate closer to 98%–99%, which rep-
resents a reasonable and achievable target for the new, excellent
DAAs.
As a proof-of-concept for a personalized approach to HCV treat-
ment in real-life, we analysed the efficacy of several first-line all-
oral regimens in patients who underwent pre-therapy assessment
of multiple clinical and virological parameters, including natural
RASs.
Methods
One hundred and thirty-one patients who started a first-line all-oral DAA
regimen between April 2015 and December 2016 were included. The
choice of treatment was based on DAA availability. Ribavirin use and treat-
ment duration were at the discretion of the investigator.
All patients were tested for natural NS3 and NS5A RASs by standard
population sequencing as described elsewhere,9 while testing for resistance
to sofosbuvir or dasabuvir was optional, and performed in 91 of 131 pa-
tients. RASs were defined according to latest updates available.3,10,11
A phylogenetic analysis by neighbour-joining method in MEGA v5.1
excluded laboratory contaminations, and assigned HCV genotype and
subtype.
SVR was defined as HCV-RNA undetectability 12 weeks after treatment
discontinuation (SVR12).
Ethics
This study was conducted in accordance with the principles of the
Declaration of Helsinki, and approval by local Ethics Committees, as well as
patient written informed consents, were obtained.
Results
Study population
Our study population was representative of a quite complex real-
life clinical context (Table 1). Infection by GT-1a and GT-3a were fre-
quent (35.9% and 19.1%, respectively), concordantly with a high
prevalence of patients with a history of drug addiction (28.2%), in
50% of cases still active (19 of 37). In addition, 67.2% of patients
had an F4 cirrhosis with remarkable stiffness [median (IQR)"20.2
(13.4–30.4) kPa]; seven had liver decompensation, three with hepa-
tocellular carcinoma. Nearly half of patients (43.5%) were IFN
experienced (including 27 previous non-responders) and 10 (7.6%)
had previously failed a first-generation PI (boceprevir/telaprevir).
Median (IQR) baseline HCV-RNA was 5.8 (5.2–6.4) log IU/mL and
46.2% of patients had values800000 IU/mL.
Overall, 74.0% of patients presented 2 risk factors for failure
to achieve SVR12 (infection by HCV GT-1a or GT-3a; cirrhosis; previ-
ous treatment with IFN-based regimens; baseline HCV-RNA
800000 IU/mL) and 33.6% had3 factors.
Comorbidities included non-Hodgkin lymphoma (3.8% preva-
lence), b-thalassaemia (3.8%), type 2 diabetes (3.1%), cryoglobuli-
naemia (2.3%), psoriasis (2.3%), end-stage kidney failure (1.5%)
and monoclonal gammopathy (1.5%). Prevalence of HIV coinfec-
tion was 6.9%.
Baseline resistance
Before the start of treatment, the presence of at least one RAS for
currently recommended DAA regimens was found in 42 of 131 pa-
tients (32.1%) (Table S1, available as Supplementary data at JAC
Online). No RASs were detected in the coinfected GT-1a/GT-3a pa-
tient or in the patient infected with GT-4a.
NS3 RASs for simeprevir/paritaprevir/grazoprevir were found in
25 of 131 patients (19.1%), mainly GT-1b infected (14 of 36,
38.9%), due to frequent detection of Y56F grazoprevir RAS (10 of
36, 27.8%).
NS5A RASs for daclatasvir/elbasvir/ledipasvir/ombitasvir/velpa-
tasvir were found in 20 of 131 patients (15.3%), including 4 of
47 GT-1a (8.5%), 7 of 36 GT-1b (19.4%), 2 of 11 GT-2c (18.2%) and
7 of 25 GT-3a (28.0%). Double RASs were detected in six patients
and triple RASs in one GT-1a (M28V!Q30R! L31M). Most fre-
quent NS5A RASs were Y93H in GT-1b (3 of 36, 8.3%) and GT-3a
(3 of 25, 12.0%) and F28C in GT-2c (2 of 11, 18.2%).
NS5B RASs were detected only in 7 of 91 patients (7.7%), of
whom 6 were GT-1b. The sofosbuvir RAS S282T was never
detected.
Phylogenetic analysis of HCV sequences disclosed the wrong
genotype classification in one patient (GT-1a instead of GT-3a) and
resolved undetermined genotyping results by commercial assays
in three other cases (GT-1a, GT-1b and GT-3a, respectively).
Treatment personalization and efficacy
According to GRT results, HCV genotype and subtype assigned by
phylogenetic analysis, liver status, previous treatment experience
and other clinical predictors of response, patients started a first-
line, tailored DAA regimen (Figure 1).
In this personalized-treatment cohort, the PP SVR12 rate was
100% (130 of 130) (Figure 1). One GT-4d patient died due to stage
IV mantellar lymphoma after 8 weeks of treatment; viraemia at
that time was stably undetectable.
Personalized regimens were in accordance with current recom-
mendations from the European Association for the Study of the
Liver (EASL; update of September 2016) in 84 of 131 patients
(64.1%), of whom 28 had baseline RASs and 56 did not. Thirty-
three other patients (25.2%) who started therapy before
September 2016 were treated with DAA regimens no longer con-
sidered optimal by EASL recommendation 2016–17 (i.e. sofosbu-
vir! simeprevir for GT-1, sofosbuvir! ribavirin for GT-2), but that
were recommended by EASL indications of 2015.
Baseline RASs contributed to a modification of treatment sched-
ule in 14 patients (10.7%) for whom a DAA combination was specif-
ically chosen among those available (n"3), and/or strengthened
(by ribavirin inclusion and/or duration increase, n"4) or simplified
(by ribavirin exclusion and/or duration reduction,n"8).
In two GT-1a patients and one GT-1b non-cirrhotic patient, DAA
regimens were chosen based on the resistance profile among
those available. Indeed, one GT-1a patient received 24 weeks of
daclatasvir! sofosbuvir! ribavirin due to the presence of Q80K in
NS3 and Y93C in NS5A, while the other GT-1a patient was treated
with sofosbuvir! simeprevir! ribavirin for 12 weeks due to the
presence of M28V NS5A RAS. The GT-1b patient received 12 weeks
of sofosbuvir/ledipasvir due to the presence of dasabuvir RAS
C316H.
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Similarly, in three other patients with natural RASs, currently rec-
ommended DAA regimens were ‘strengthened’ by prolonging treat-
ment duration to 24 weeks or by adding ribavirin. In particular, one
GT-3a patient received 24 weeks of daclatasvir! sofosbuvir! ribavirin
due to the presence of A62L NS5A RAS, while two GT-1b patients
received daclatasvir! sofosbuvir for 24 weeks and sofosbuvir/ledipas-
vir! ribavirin for 12 weeks due to double-class NS5A!NS5B resist-
ance (NS5A:P58A; NS5B:C445F!V321A) in one patient and the
presence of L159F NS5B RASs plus a very high viral load and complex
clinical situation in the other patient.
On the other hand, regimens were simplified by ribavirin
exclusion and/or duration reduction from 24 weeks to 12, in eight
cirrhotic GT-1a or GT-3a patients without baseline NS5A RASs.
Lastly, in two patients with no baseline RASs, other negative
predictors of response contributed to the choice of a more in-
tense regimen (longer and/or with ribavirin) than those sug-
gested by EASL indications 2016. These included previous PI
experience, high baseline HCV-RNA and cirrhosis with high stiff-
ness values.
Discussion
In this study, we provided a proof-of-concept for a ‘tailored’ DAA
regimen that associates baseline evaluation of HCV resistance to
DAAs to the other clinical parameters universally considered es-
sential for treatment personalization. Treatment personalization
Table 1. Study population (N"131)
HCV genotype, n (%) 1a 47 (35.9)
1a/3a coinfection 1 (0.8)
1b 36 (27.5)
2c 11 (8.4)
3a 25 (19.1)
4a 1 (0.8)
4d 10 (7.6)
Treatment naive, n (%) 74 (56.5)
Previous virological failure, n (%) breakthrough 3 (2.3)
non-responder 27 (20.6)
relapse 17 (13.0)
Previous treatment discontinuation, n (%) adverse events 5 (3.8)
drop-out 1 (0.8)
unknown 4 (3.1)
Previous PI experience, n (%) 10 (7.6)
Liver stiffness (kPa), median (IQR) 13.6 (10.8–25.1)
Metavir, n (%) F1 1 (0.8)
F2 3 (2.3)
F3 39 (29.8)
F4 88 (67.2)
Child–Turcotte–Pugh class, n (%)a CTP-A 70 (53.4)
CTP-B 7 (5.3)
HIV coinfection, n (%) 9 (6.9)
Hepatocellular carcinoma, n (%) 3 (2.3)
HCV-related extrahepatic manifestations, n (%) cryoglobulinaemia 3 (2.3)
monoclonal gammopathy 2 (1.5)
non-Hodgkin lymphoma 5 (3.8)
psoriasis 3 (2.3)
type 2 diabetes 4 (3.1)
end-stage kidney failure 2 (1.5)
Haemophilia A, n (%) 1 (0.8)
b-Thalassaemia, n (%) 5 (3.8)
HCV-RNA (log IU/mL), median (IQR) 5.8 (5.2–6.4)
ALT (IU/mL), median (IQR) 78 (46–131)
AST (IU/mL), median (IQR) 56 (33–97)
Platelets (n/mm3), median (IQR) 161000 (118000–241000)
Creatinine (mg/dL), median (IQR) 0.8 (0.7–1.0)
Bilirubin (mg/dL), median (IQR) 0.8 (0.53–1.23)
Albumin (mg/dL), median (IQR) 4 (3.9–4.0)
aInformation available for 77 patients.
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following this approach led to 100% PP SVR, even in patients
whose ‘tailored’ treatment did not precisely meet current interna-
tional recommendations.3 Indeed, baseline RAS presence or ab-
sence contributed to the selection of a different DAA combination
or to ‘simplified’ or ‘strengthened’ treatment protocols by ribavirin
use and/or modulation of treatment.
Our population was representative of a quite complex real-life
clinical context, with a high prevalence (74.0%) of patients show-
ing 2 risk factors for treatment failure and with important extra-
hepatic comorbidities that could significantly complicate anti-HCV
treatment.3 A significant number of the patients we included had
a history of drug addiction (28.2%, of whom 50% were still active
drug-users), which accounted for the high prevalence of GT-3a
and GT-1a infection in our population.
Thanks to baseline GRT, we were able to disclose natural RAS
presence in 32.1% of patients analysed and more frequently in
those infected by GT-1b, GT-2c and GT-3a. In addition, we also cor-
rectly attributed infecting HCV genotype in four patients, highlight-
ing a case of wrong genotype assignation by commercial assays
that would have led to an inappropriate treatment regimen (GT-3a
versus GT-1a).
From our perspective, ‘personalization’ of first-line DAA regi-
mens can take advantage of the evaluation of viral resistance pro-
file, provided that a reliable methodology and proper results’
interpretation flowchart are developed and easily accessible
(as correctly proposed in a recent review).12 In this case, resistance
information may contribute to a reliable a priori evaluation of the
likelihood of response at the individual patient level. In specific
situations, this can help identify those patients, who for social rea-
sons or comorbidities, may benefit from the use of short and/or
ribavirin-free therapies. In these patients, a baseline profile of no
viral resistance would support treatment ‘simplification’. Similarly,
it can be fruitfully used to define which patients can take advan-
tage of increasing drug pressure by a proper DAA regimen, and/or
of adding ribavirin or prolonging treatment, as previously sug-
gested by clinical trials.4,8,13,14 Further evidences is required to sup-
port the observations obtained in this proof-of-concept study, and
we have to be aware that our GRT-guide approach to simplification
of DAA regimens (shortening of therapy and no use of ribavirin
with current drugs) was applied only for first-line IFN-free regi-
mens. Currently, no data are available for DAA-experienced sub-
jects in real-life, in whom retreatment ‘simplification’ would
potentially be risky.
In conclusion, in DAA-naive patients, baseline resistance evalu-
ation integrated with clinical and virological parameters may play
a relevant role in bringing the rate of success close to the highest
achievable rate.
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Figure 1. SVR rates according to treatment regimen. Histograms represent individual PP SVR rates for each DAA regimen, categorized according to
current EASL recommendations (2016) and HCV genotype/subtype. Within each regimen category, the percentages of patients receiving a 12 week
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